Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 32.5% in May

Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 31,800 shares, a growth of 32.5% from the May 15th total of 24,000 shares. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 2.0% of the shares of the stock are short sold.

Bio-Path Stock Up 8.0 %

BPTH stock traded up $0.16 during midday trading on Friday, hitting $2.16. The stock had a trading volume of 5,048,178 shares, compared to its average volume of 3,034,077. Bio-Path has a 12-month low of $1.85 and a 12-month high of $44.80. The company’s 50-day moving average price is $2.68 and its 200 day moving average price is $6.17.

Bio-Path (NASDAQ:BPTHGet Free Report) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.54) by ($0.34). As a group, sell-side analysts expect that Bio-Path will post -9.68 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Roth Mkm reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Bio-Path in a research note on Thursday, April 18th. started coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They issued a “sell” rating on the stock.

Read Our Latest Stock Analysis on Bio-Path

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Articles

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.